High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients.

The American Cancer Society reported about 100 000 new melanoma cases and 7300 estimated patient deaths in 2019 with an increasing trend of both incidence and death rates. 1 About 50% of patients carry a somatic mutation of the BRAF gene, which encodes for a serine-threonine kinase involved in the control of the MAPK pathway (BRAF/MEK/ERK). 2 The BRAF p.V600E (c. 1799T > A) pathogenic variant is detected in up to 90% of the BRAF -mu

also in 63,971 other papers